Navigation Links
Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.
Date:5/21/2013

Mississauga, Ontario (PRWEB) May 21, 2013

Inflamax scientists worked closely with internationally renowned expert scientists of the ITN to design the study, which will provide critical insight into the usefulness of two key clinical models used in the study of allergy treatments, the Environmental Exposure Chamber (EEC) and Nasal Allergen Challenge (NAC) models. Although both the models are well recognized and supported by numerous publications, to date no direct comparison between the allergic responses evoked by them has been performed.

The study involves allergen challenge by the two methods, followed by collection of nasal secretions and blood work to identify the sequence of biomarkers and inflammatory cells involved in the early and late phase of the allergic reaction. Dr. Stephen Durham from the Imperial College London developed the NAC model, and he will be the study’s coordinating investigator. The protocol is being developed by Inflamax and the team at ITN.

“We are pleased that ITN and its group of internationally renowned scientists and clinicians, after reviewing the other available EEC facilities, chose to collaborate with Inflamax on this project. This highlights the unique and very high caliber of scientific expertise and experience that we provide. Collaborations and projects like this underline our core vision and mission to develop and provide the best, scientifically validated models to our clients.” Says Dr Piyush Patel, MD, CEO of Inflamax Research. “Inflamax provides the best of client focused CRO services with scientific expertise which is unparalleled even in the top academic institutions”.

“Sponsor organizations wishing to conduct clinical trials utilizing allergen challenge models including the EEC, need to ensure that the study is properly designed. So doing this kind of basic research reinforces the confidence in data validity, and increases the likelihood that regulators around the world accept the data. The scientific staff at Inflamax have designed and conducted many mechanistic, proof of concept and pivotal studies utilizing multiple allergen challenge models, and are the experts in both scientific design and EEC trial methodology.” says Dr. Anne Marie Salapatek, President and CSO of Inflamax.

Inflamax is developing in-house capability to measure biomarkers and has the expertise to recommend specific biomarkers to assay in order to understand the underlying mechanism of action. Typical markers for consideration may include IL1, IL5, Eosinophil Cationic Protein (ECP), tryptase and Th2 cytokines, specific immunoglobulin (IgG, IgG4, IgA, IgE, and FAB), basophil activation and HLA assays.

About Inflamax

Inflamax is a full service Contract Research Organization (CRO) specializing in Proof of Concept as well as Phase I through IV studies in allergy, asthma, ocular and dermatology utilizing EEC technology. Inflamax conducts single and multi-center Environmental Exposure Chamber (EEC) and field studies. In addition to Inflamax Research’s Mobile EECTM systems which can be positioned globally, Inflamax has 2 fixed EECs at Inflamax headquarters in Toronto, Canada. Inflamax’s EECs have been validated for study of allergy to ragweed, grass, cat and dust mite, as well as dry eye syndrome (utilizing low humidity EEC conditions).

About ITN

The Immune Tolerance Network (ITN) is an international clinical research consortium sponsored by NIAID, part of the National Institutes of Health.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10742734.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
2. Inflamax Research Appoints Dr. Anne Marie Salapatek President & Chief Scientific Officer
3. Inflamax Research Introduces Electronic Patient Data Acquisition Tablet™ (ePDAT)™ for Real-Time PRO Data Collection
4. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials
5. Vital Imaging Makes Greater Commitment into MRI Research
6. Phosphagenics Signs Research Agreement with the Agricultural Research Service
7. Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group
8. Researchers identify signals that direct the immune system to reject a transplanted organ
9. NIH Saves Lives: Fred Hutchinson Cancer Research Center Calls On Congress To Restore Full NIH Funding
10. The Research Foundation for The State University of New York Enters Site License Agreement with 2Market Information Inc., Publisher of Technology Transfer Tactics
11. Contraceptives Market is Expected to Reach USD 23.3 Billion Globally in 2018: Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Boston, MA (PRWEB) , ... April 28, 2016 ... ... (EDT), Asymmetrex will deliver a talk on its first-in-class technologies for ... the 2016 Meeting on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome ...
(Date:4/27/2016)... ... ... Cambridge Semantics, the leading provider of Smart Data analytic and ... named to The Silicon Review’s “20 Fastest Growing Big Data Companies of 2016.” ... needs of end users facing some of the most complex data challenges in the ...
(Date:4/27/2016)... ... April 27, 2016 , ... Most consumers engage ... fingerprint recognition for secure access, voice recognition for hands-free communication, and facial recognition ... interacting with biometrics technology today. But if they asked Joey Pritikin, Vice ...
(Date:4/27/2016)... British Virgin Islands (PRWEB) , ... April 27, ... ... Holding Company Ltd. (d/b/a Biohaven) is pleased to announce the appointment of John Tilton ... he was an Executive Director and one of the founding commercial leaders responsible ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/21/2016)... March 22, 2016 Unique ... passcodes for superior security   ... provider of secure digital communications services, today announced it ... and offer enterprise customers, particularly those in the Financial ... and voice authentication within a mobile app, alongside, and ...
(Date:3/14/2016)... -- NXTD ) ("NXT-ID" or the "Company"), a ... airing of a new series of commercials on Time Warner ... st .  The commercials will air on Bloomberg TV, Fox ... Street show. --> NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ...
Breaking Biology News(10 mins):